Immunovant Sciences Gmbh
Clinical trials sponsored by Immunovant Sciences Gmbh, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New shot could tame lupus skin flares Results expected Oct 2026 (estimated)
- New drug aims to tame overactive thyroid without lifelong pills Results expected May 2027 (estimated)
- New shot could help when arthritis drugs fail Results expected Sep 2027 (estimated)
-
New drug batoclimab shows promise for Hard-to-Treat Graves' disease
Disease control CompletedThis study tested a drug called batoclimab in 35 adults with Graves' disease whose thyroid hormone levels were still high despite taking standard antithyroid drugs. The goal was to see if batoclimab could help bring those levels back to normal or below over 24 weeks. Batoclimab w…
Phase 2 • Sponsor: Immunovant Sciences GmbH • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New drug batoclimab aims to reduce eye bulging in thyroid eye disease
Disease control CompletedThis Phase 3 trial tested whether batoclimab, an injected antibody, can reduce eye bulging (proptosis) in people with active, moderate-to-severe thyroid eye disease. 86 participants received weekly injections of batoclimab or a placebo for 24 weeks. The main goal was to see how m…
Phase 3 • Sponsor: Immunovant Sciences GmbH • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New drug shows promise for bulging eyes in thyroid disease
Disease control CompletedThis Phase 3 trial tested a drug called batoclimab in 114 adults with active, moderate-to-severe thyroid eye disease (TED). Participants received weekly injections of batoclimab or a placebo for 24 weeks. The main goal was to see if the drug could reduce eye bulging (proptosis) b…
Phase 3 • Sponsor: Immunovant Sciences GmbH • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC